title: Autoimmune and infectious skin diseases that target desmogleins.
abstract: Desmosomes are intercellular adhesive junctions of epithelial cells that contain two major transmembrane components, the desmogleins (Dsg) and desmocollins (Dsc), which are cadherin-type cell-cell adhesion molecules and are anchored to intermediate filaments of keratin through interactions with plakoglobin and desmoplakin. Desmosomes play an important role in maintaining the proper structure and barrier function of the epidermis and mucous epithelia. Four Dsg isoforms have been identified to date, Dsg1-Dsg4, and are involved in several skin and heart diseases. Dsg1 and Dsg3 are the two major Dsg isoforms in the skin and mucous membranes, and are targeted by IgG autoantibodies in pemphigus, an autoimmune disease of the skin and mucous membranes. Dsg1 is also targeted by exfoliative toxin (ET) released by Staphylococcus aureus in the infectious skin diseases bullous impetigo and staphylococcal scalded skin syndrome (SSSS). ET is a unique serine protease that shows lock and key specificity to Dsg1. Dsg2 is expressed in all tissues possessing desmosomes, including simple epithelia and myocardia, and mutations in this gene are responsible for arrhythmogenic right ventricular cardiomyopathy/dysplasia. Dsg4 plays an important adhesive role mainly in hair follicles, and Dsg4 mutations cause abnormal hair development. Recently, an active disease model for pemphigus was generated by a unique approach using autoantigen-deficient mice that do not acquire tolerance against the defective autoantigen. Adoptive transfer of Dsg3(-/-) lymphocytes into mice expressing Dsg3 induces stable anti-Dsg3 IgG production with development of the pemphigus phenotype. This mouse model is a valuable tool with which to investigate immunological mechanisms of harmful IgG autoantibody production in pemphigus. Further investigation of desmoglein molecules will continue to provide insight into the unsolved pathophysiological mechanisms of diseases and aid in the development of novel therapeutic strategies with minimal side effects.
authors.affiliation: Department of Dermatology, Keio University School of Medicine, Tokyo, Japan. amagai@sc.itc.keio.ac.jp
authors.forename: Masayuki
authors.initials: M
authors.lastname: Amagai
mesh_terms: D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000276:immunology*; D051182:Desmogleins / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D020033:Protein Isoforms / Q000276:immunology; D012874:Skin Diseases, Infectious / Q000175:diagnosis / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D051182:Desmogleins; D007074:Immunoglobulin G; D020033:Protein Isoforms
references.citation: J Immunol. 1997 Aug 15;159(4):2010-7
references.pmid: 9257868
references.citation: J Clin Invest. 2004 Nov;114(10):1484-92
references.pmid: 15545999
references.citation: N Engl J Med. 1982 May 20;306(20):1189-96
references.pmid: 7040962
references.citation: N Engl J Med. 1990 Dec 20;323(25):1729-35
references.pmid: 2247105
references.citation: Br J Dermatol. 2002 Aug;147(2):261-5
references.pmid: 12174096
references.citation: J Clin Invest. 1992 Sep;90(3):919-26
references.pmid: 1522242
references.citation: Exp Cell Res. 1994 Apr;211(2):391-9
references.pmid: 8143788
references.citation: Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2264-71
references.pmid: 8637861
references.citation: Am J Hum Genet. 2006 Jul;79(1):136-42
references.pmid: 16773573
references.citation: J Invest Dermatol. 1995 Jan;104(1):27-32
references.pmid: 7528244
references.citation: Circulation. 2006 Mar 7;113(9):1171-9
references.pmid: 16505173
references.citation: Exp Dermatol. 2009 Mar;18(3):252-60
references.pmid: 18643850
references.citation: Science. 1989 Nov 24;246(4933):982
references.pmid: 2686027
references.citation: J Invest Dermatol. 2006 Sep;126(9):2139-41
references.pmid: 16691200
references.citation: J Invest Dermatol. 2008 Apr;128(4):939-48
references.pmid: 18007588
references.citation: J Invest Dermatol. 1995 Jan;104(1):146-52
references.pmid: 7798634
references.citation: Biochemistry. 1999 Aug 10;38(32):10239-46
references.pmid: 10441117
references.citation: Br J Dermatol. 1999 Feb;140(2):351-7
references.pmid: 10233237
references.citation: Adv Dermatol. 1997;12:77-96; discussion 97
references.pmid: 8973736
references.citation: JAMA. 1992 Mar 18;267(11):1500-2
references.pmid: 1538540
references.citation: J Immunol. 2009 Feb 1;182(3):1740-5
references.pmid: 19155523
references.citation: J Immunol. 2003 Feb 15;170(4):2170-8
references.pmid: 12574390
references.citation: J Clin Invest. 2005 Apr;115(4):888-99
references.pmid: 15841178
references.citation: Nat Med. 2000 Nov;6(11):1275-7
references.pmid: 11062541
references.citation: Nature. 1995 Mar 23;374(6520):327-37
references.pmid: 7885471
references.citation: N Engl J Med. 1970 May 14;282(20):1114-9
references.pmid: 4245327
references.citation: Biochemistry. 1997 Feb 18;36(7):1559-66
references.pmid: 9048539
references.citation: J Clin Invest. 2000 Mar;105(5):625-31
references.pmid: 10712434
references.citation: Hum Mol Genet. 1999 Jun;8(6):971-6
references.pmid: 10332028
references.citation: Science. 1991 Mar 22;251(5000):1451-5
references.pmid: 2006419
references.citation: Structure. 1997 Jun 15;5(6):813-24
references.pmid: 9261066
references.citation: Eur J Immunol. 2002 Mar;32(3):627-33
references.pmid: 11857336
references.citation: Science. 2002 May 17;296(5571):1308-13
references.pmid: 11964443
references.citation: J Invest Dermatol. 1990 Mar;94(3):327-31
references.pmid: 2307852
references.citation: J Invest Dermatol. 1976 Aug;67(2):254-60
references.pmid: 950490
references.citation: N Engl J Med. 2006 Oct 26;355(17):1800-10
references.pmid: 17065642
references.citation: Cell. 2003 Apr 18;113(2):249-60
references.pmid: 12705872
references.citation: Cell. 1990 Apr 6;61(1):147-55
references.pmid: 2317870
references.citation: Infect Immun. 2002 Oct;70(10):5835-45
references.pmid: 12228315
references.citation: J Invest Dermatol. 1995 Jun;104(6):895-901
references.pmid: 7539469
references.citation: J Cell Biol. 1997 Jun 2;137(5):1091-102
references.pmid: 9166409
references.citation: J Immunol. 2008 Jul 15;181(2):1526-35
references.pmid: 18606708
references.citation: J Clin Invest. 1982 Aug;70(2):281-8
references.pmid: 7047566
references.citation: Proc Soc Exp Biol Med. 1964 Nov;117:505-10
references.pmid: 14233481
references.citation: Cell. 1991 Nov 29;67(5):869-77
references.pmid: 1720352
references.citation: Br J Dermatol. 1971 Jan;84(1):7-13
references.pmid: 5573187
references.citation: N Engl J Med. 1999 May 6;340(18):1406-10
references.pmid: 10228191
references.citation: Eur J Cell Biol. 1990 Oct;53(1):1-12
references.pmid: 1706270
references.citation: J Invest Dermatol. 2002 May;118(5):845-50
references.pmid: 11982763
references.citation: J Dermatol Sci. 1999 Jun;20(2):92-102
references.pmid: 10379702
references.citation: J Invest Dermatol. 2002 Jan;118(1):199-204
references.pmid: 11851895
references.citation: J Clin Invest. 1999 Feb;103(4):461-8
references.pmid: 10021453
references.citation: Nat Rev Mol Cell Biol. 2000 Dec;1(3):208-16
references.pmid: 11252896
references.citation: J Immunol. 2001 Nov 1;167(9):5439-48
references.pmid: 11673563
references.citation: J Clin Invest. 1994 Jul;94(1):59-67
references.pmid: 8040292
references.citation: Nature. 1987 Sep 24-30;329(6137):341-3
references.pmid: 3498123